Question 1

What are the potential side effects of prexasertib and ralimetinib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer clinical trial (NCT02860780). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer clinical trial (NCT02860780). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer clinical trial (NCT02860780). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any specific tests or procedures I need to undergo?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer clinical trial (NCT02860780). Contact the study team or your healthcare provider for specific answers.

Question 5

How will this trial affect my overall treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer clinical trial (NCT02860780). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer clinical trial (NCT02860780). Contact the study team or your healthcare provider for specific answers.

What this study is about